Zulresso Indicated for Postpartum Depression in Adolescents

June 22, 2022

Zulresso (brexanolone) has obtained an expanded indication to treat postpartum depression (PPD) in patients who are at least 15 years old.

  • In 2019, the FDA approved Zulresso to treat PPD in adults. The drug is administered via intravenous infusion under the supervision of a qualified healthcare professional.
  • A full course of treatment requires 60 hours and follows a recommended dosing schedule of:
    • 0 to 4 hours: Initiate with a dosage of 30mcg/kg of the patient’s weight per hour.
    • 4 to 24 hours: Increase dosage to 60mcg/kg/hour.
    • 24 to 52 hours: Increase dosage to 90mcg/kg/hour (or consider a dosage of 60mcg/kg/hour for individuals unable to tolerate 90mcg/kg/hour).
    • 52 to 56 hours: Decrease dosage to 60mcg/kg/hour.
    • 56 to 60 hours: Decrease dosage to 30mcg/kg/hour.
demo-attachment-261-Group-56
demo-attachment-606-Group-43
demo-attachment-1121-Rectangle-602

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager
demo-attachment-180-Group-4